関連文献

Nonalbuminuric proteinuria as a biomarker for tubular damage in early development of nephropathy with type 2 diabetic patients.

Diabetes Metab Res Rev. 30(8): 736-741, 2014.PubMed

Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.

AIDS Res Hum Retroviruses. 30(4): 363-369, 2014.PubMed

Moderate-intensity single exercise session does not induce renal damage.

J Clin Lab Anal. 27(3): 177-180, 2013.PubMed

A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.

Am J Physiol Renal Physiol. 305(12): F1796-1803, 2013.PubMed

Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy.

Diabetes Care. 36(5): 1248-1253, 2013.PubMed

Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.

Diabet Med. 29(8): e184-190, 2012.PubMed

Renoprotective and antioxidant effects of cilnidipine in hypertensive patients.

Hypertens Res. 35(11): 1058-1062, 2012.PubMed

Potential Benefit of Statin Therapy for Dyslipidemia with Chronic Kidney Disease: Fluvastatin Renal Evaluation Trial (FRET).

Internal Medicine. 50(12): 1273-1278, 2011.PubMed

Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.

Hypertens Res . 34: 935-941, 2011.PubMed

Protective effects of tubular liver-type fatty acid-binding protein against glomerular damage in murine IgA nephropathy.

Nephrol Dial Transplant. 26(7): 2127-2137, 2011.PubMed